The case for & against
Bull & Bear analysis
Bearish
Avid Bioservices, Inc. was primarily known for its operations within the Contract Development and Manufacturing Organization (CDMO) sector before its acquisition by GHO Capital Partners and Ampersand Capital Partners in February 2025. The company was leading in biologics manufacturing, offering comprehensive development and manufacturing services for complex biologics. Despite its delisting, the broader CDMO industry remains robust, with significant growth projected due to increased outsourcing trends in pharmaceuticals and biotechnology.
Bull says
- ↑Global CDMO market grows from $191 B in 2026 to $270.3 B by 2031 (7.2% CAGR)
- ↑$3.1 M in committed CDMO orders points to rising client demand
- ↑35+ years’ leadership hires at peers underscore sector expertise trend
- ↑Manufacturing tech advancements likely improve efficiencies and margins
- ↑Outsourcing surge for complex biologics drives long-term CDMO growth
- ↑Strong momentum factors and positive earnings revisions support upside
Bear says
- ↓Delisting after private acquisition reduces financial transparency
- ↓Global peers (Lonza, Samsung, Fujifilm) intensify pricing and share pressures
- ↓Pharma budget shifts and contract volatility risk revenue consistency
- ↓Leadership and strategy shifts post-acquisition may hamper execution
- ↓Falling behind on tech innovation could erode historical competitive moat
- ↓Lack of public metrics and uncertain factor exposure raise caution